Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-10-27Clinical Trial Update: Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD [Phase 2]
Phase 2 trial updates on SPN-812 (viloxazine ER) for ADHD in children show efficacy and safety data.
-
CLINICAL_TRIALS trial_result · 2021-10-18Clinical Trial Update: A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder [Phase 3]
Phase 3 trial evaluating centanafadine sustained-release tablets for adults with ADHD has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-18Clinical Trial Update: Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder [Phase 2]
Phase 2 trial evaluating flexible doses of EB-1020 SR for adult ADHD has been completed with results posted.
-
FDA approval · 2021-09-29FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic product containing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphe…
-
CLINICAL_TRIALS research · 2021-09-20Clinical Trial Update: Pharmacokinetics of HLD200 in Children and Adolescents With ADHD [Phase 1, Phase 2]
A pharmacokinetics study of HLD200 in children and adolescents with ADHD, completed with results posted in 2021.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2021-09-16Clinical Trial Update: Real World Evidence of the Efficacy and Safety of FOQUEST [Phase 4]
Phase 4 real-world evidence trial evaluating efficacy and safety of FOQUEST in attention deficit-hyperactivity disorder has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-27Clinical Trial Update: Motivated Behavior in Adults With and Without ADHD [Phase 2]
Phase 2 clinical trial assessing motivated behavior in adults with and without ADHD has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-23Clinical Trial Update: Safety of SPD465 in Treating Adults With ADHD. [Phase 3]
Phase 3 trial update on SPD465 (attention-deficit/hyperactivity disorder) assessing safety in adults; study completed.
-
CLINICAL_TRIALS trial_result · 2021-07-26Clinical Trial Update: PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 3]
Phase 3 trial update for PRC-063 in adults with ADHD; study completed with results posted.
-
FDA approval · 2021-07-19FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)
FDA approved a supplemental application for MethyLin (methylphenidate hydrochloride) submitted by Shionogi under NDA 021419.
-
CLINICAL_TRIALS trial_result · 2021-07-19Clinical Trial Update: KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD [Phase 3]
Open-label safety study in children aged 6-12 with ADHD completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-07-19Clinical Trial Update: A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD [Phase 2]
Phase 2 trial update for a delayed and extended-release formulation of dextroamphetamine sulfate (HLD100) in children with ADHD.
-
CLINICAL_TRIALS trial_result · 2021-07-14Clinical Trial Update: Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD [EARLY_Phase 1]
Phase 1 clinical trial update investigating the prevalence of lidocaine ineffectiveness in adults with and without ADHD, with results posted…
-
CLINICAL_TRIALS trial_result · 2021-07-08Clinical Trial Update: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD [Phase 3]
Phase 3 trial evaluating high-dose viloxazine extended-release in children with ADHD has completed.
-
CLINICAL_TRIALS withdrawal · 2021-07-06Clinical Trial Update: A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators [Phase 3]
Phase 3 trial of SPD465 in young adults with ADHD using driving simulators has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-07-02Clinical Trial Update: Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD [Phase 3]
Phase 3 trial evaluating high-dose viloxazine ER (SPN-812) in adolescents with ADHD has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-02Clinical Trial Update: Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD [EARLY_Phase 1]
An early-phase observational study evaluating lidocaine ineffectiveness in hard-to-treat ADHD has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-30Clinical Trial Update: KP415 Classroom Study in Children (6-12 Years of Age) With ADHD [Phase 3]
A Phase 3 clinical trial in children aged 6-12 with ADHD has completed and posted results.
-
FDA approval · 2021-06-26FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for FOCALIN XR (dexmethylphenidate hydrochloride) submitted by Sandoz Inc.
-
FDA approval · 2021-06-26FDA Approved: FOCALIN — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for FOCALIN (dexmethylphenidate hydrochloride) filed by Sandoz Inc.
-
FDA approval · 2021-06-26FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for methylphenidate submitted by Sandoz Inc.
-
FDA approval · 2021-06-25FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the Methylphenidate Transdermal System (methylphenidate patch) by PADAGIS US LLC. The product is…
-
FDA approval · 2021-06-25FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for Methylphenidate Hydrochloride CD from Lannett Company, Inc. The approval indicates an update…
-
FDA approval · 2021-06-25FDA Approved: CONCERTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for CONCERTA (methylphenidate hydrochloride) submitted by Janssen Pharmaceuticals, Inc. This act…
-
FDA approval · 2021-06-25FDA Approved: QUILLIVANT XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for QUILLIVANT XR (methylphenidate hydrochloride) submitted by NextWave Pharmaceuticals, Inc.